editor, reviewer
547
edits
Changes
Jump to navigation
Jump to search
Line 92:
Line 92: − + − + + + + +
→The business with homeopathics
==The business with homeopathics==
==The business with homeopathics==
Germany and France are the most important markets for a homoeopathic and anthroposophic-homoeopathic medicine in Europe. Almost 60% of all medicines of these therapy directions produced in Europe were, sold '''add source'''[27] with a Europe-wide increase of 60% between 1995 and 2005 in these two countries. In Germany there was a turnover plus of 80%, in France 300%. The Europe-wide sales volume amounts to 1.7 billion Euros, about 7% of all medicine available without prescription. The revenues of the production amounted to about 930 million Euros, therefrom 810 million Euros for medicine in 2005. Measured against the manufacturer's prices about 268 million Euros of the EU sales were allotted to Germany, on France 294 million Euros. According to information from the weekly periodical of "Der Spiegel" the sales volume of homoeopathic remedies was at 400 million Euros in 2009. According to information from the federal association of the pharmaceutical industry the legal health insurance companies paid 9 million Euros for homoeopathic remedies. The subsequent costs are not, however, included for ineffective homoeopathic therapies here. The costs by homoeopathic first and subsequent case histories which must be usually paid by the patients are also not comparable with these costs. The market leading enterprise in Germany is the German homoeopathy union (DHU). The group with over 400 employees has developed out of the company Schwabe set up in 1961.
Germany and France are the most important markets for both homoeopathic and anthroposophic-homoeopathic remedies in Europe. Almost 60% of all medicines of these therapy concepts produced in Europe were sold in these two countries '''add source'''[27], with a Europe-wide increase of 60% between 1995 and 2005. German sales saw a turnover plus amounting to 80%, while figures in France increased by 300%. Europe-wide sales volumes amount to 1.7 billion Euros, about 7% of all non-prescription drugs. In 2005, produce revenues amounted to approx. 930 million Euros, with 810 million Euros thereof for medicine.
The most used homeopathic is Oscilococcinum C200. This remedy also is called the "20 million canard". The annual turnover for the product is 20 million dollars. The remedy is produced from duck liver, but only the liver of one single duck is used for the complete sales volume, and of this something is left: The potentization of C200 means that the ratio of liver to the solution 1 to 10 is with 400 zeros.
Measured by producer's prices, about 268 million Euros of the EU sales were effected in Germany, and 294 million Euros in France. According to information from weekly periodical "Der Spiegel", sales volumes for homoeopathic remedies amounted to 400 million Euros in 2009. According to information from Federal Association of Pharmaceutical Industry, statutory health insurance companies paid 9 million Euros for homoeopathic remedies. However, follow-up costs incurring due to ineffective homoeopathic therapies are not included in this figure. Costs for homoeopathic first and follow-up anamneses are not included, either, since these usually have to be paid by patients.
In Germany, German Homoeopathic Union (DHU) are the leading providers. This corporation with more than 400 employees emerged from Schwabe company founded in 1961.
The most commonly used homeopathic in the USA is Oscilococcinum C200. This remedy also goes by the name of "20 million canard". Annual turnover for this product adds up to 20 million dollars. The remedy is produced from duck liver, but the complete sales volume does not need more than one single liver - with considerable left-overs remaining from this one piece: A dilution of C200 means a liver to solution ratio of 1 to 10 and 400 ciphers.
==Homoeopathy is financially interesting for doctors==
==Homoeopathy is financially interesting for doctors==